Kerecis has long focused on developing regenerative technologies designed to support tissue regeneration in complex wound environments, including those affecting veteran populations at risk of limb loss. That focus was recently reflected in new language included by the U.S. House Appropriations Committee in its Fiscal Year 2027 Military Construction and Veterans Affairs (MilCon/VA) appropriations report, which highlights the role regenerative technologies can play in advancing limb preservation and value‑based care within the Veterans Health Administration (VHA).
In the report, the Committee acknowledges the ongoing burden of chronic, complex, and non‑healing wounds among veterans, citing their impact on morbidity, disability, and long‑term healthcare costs. Within this context, the Committee references commercially available fish‑skin–derived regenerative wound products for their demonstrated potential to support healing, reduce complications, and contribute to limb‑sparing treatment strategies. The report further urges the VHA to promote greater consistency in formulary access and clinical availability of regenerative wound products across VA medical centers and Veterans Integrated Service Networks (VISNs).
Kerecis’ intact fish‑skin graft technology originated from early research and development efforts informed by military and trauma‑related use cases. Over time, this work has evolved into a regenerative approach designed to support healing in some of the most challenging wound presentations, including those commonly encountered in limb‑preservation and amputation‑prevention initiatives.
Preventing avoidable amputations and supporting functional recovery remain central objectives across VA programs focused on limb preservation. As these efforts continue, consistency of access to regenerative options plays a critical role in ensuring that clinical teams can apply appropriate solutions based on patient need rather than geography.
Kerecis remains committed to supporting responsible, evidence‑based engagement across the VA network by providing clinical data, educational resources, and collaborative support aligned with the VA’s goals for limb preservation and value‑driven care. The company views the Committee’s report language as a constructive indicator of progress within a complex healthcare system and as one of several factors helping shape future access and implementation discussions over time.
The full report can be read here.
From the town of Ísafjörður in northwest Iceland, Kerecis develops, manufactures, and distributes patented fish-skin medical devices that support soft tissue regeneration in the body, with regulatory clearance in the United States, Europe, and beyond.
